GERD: Gastroesophageal reflux disease; H+, K+-ATPase: Hydrogen potassium adenosine triphosphatase; PPI: Proton pump inhibitor, Vonoprazan.
Although PPIs have been used as a first-line treatment for more than a quarter-century, several issues have emerged that highlight the need for improvement:1
Delayed Onset of Action: Two-thirds of GERD patients experience insufficient symptom relief after the first PPI dose due to the drug's slow onset, and half still have symptoms after 3 days of treatment.
Genetic Variability: The efficacy of PPIs is affected by cytochrome P450 (CYP) 2C19 polymorphism.
Suboptimal Nighttime Efficacy: PPIs often do not provide adequate relief of symptoms at night.
Stability Issues: PPIs require an acidic environment for activation but are unstable in acidic conditions, necessitating enteric coating.
VONOprazan to the rescue!
VONOprazan achieves maximal and
steady-state acid inhibition more
effectively after the first dose than
conventional PPIs.
It elevates night-time pH to above
4 on the first day. Sustained daily
use maintains this pH level,
preventing the activation of pepsin
produced by chief cells.
Therefore, VONOprazan is a strong acid blocker that has rapid, stable, and long-lasting effects and these effects are found to be stronger than conventional PPIs.
GERD: Gastroesophageal reflux disease; H+, K+-ATPase: Hydrogen potassium adenosine triphosphatase; PPI: Proton pump inhibitor.
1. Oshima T, Miwa H. Potent potassium-competitive acid blockers: A new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334–344.
LMRC Code: GGI-CO-A1-AQS-300041558-APPEMC-H24-1492 DOI of 25/08/2024 & DOE of 30/11/2024
For the use of a Registered Medical Practitioner, Hospital or Laboratory only.
The images are for illustrative representation only and do not depict actual medical products, procedures, or outcomes. Refer to official medical guidance and product information for accurate details.
All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy’s Laboratories Ltd. including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted, or stored in any form without the written permission of Dr. Reddy’s.
